ClinicalTrials.gg
RecruitingNCT07940010Updated Nov 16, 2026

Effects of Creatine Formulations on Exercise and Cognitive Performance

An interventional study of Creatine Monohydrate and Multi-Ingredient Creatine Formulation in Exercise Performance and Cognitive Performance, sponsored by University of Northern Iowa. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Northern Iowa · Not applicable, Interventional, and Basic science

How we know

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study will examine whether a multi-ingredient creatine supplement produces different effects on exercise performance, cognitive function, hydration, and gastrointestinal symptoms compared with creatine monohydrate alone.

Approximately 16 healthy, physically active adults aged 18-40 years will participate. Each participant will take creatine monohydrate (5 grams per day) for 18 days and a multi-ingredient supplement containing creatine monohydrate (5 grams), sodium, potassium, magnesium, and taurine for another 18 days. The order of supplementation will be randomly assigned, with a 30-day break between conditions.

Participants will complete laboratory testing before and after each supplementation period. Testing will include bench press exercise to assess muscular endurance, repeated high-intensity cycling tests to assess exercise performance, and a computerized cognitive task to measure attention and reaction time. Researchers will also assess hydration, selected blood markers, perceived exertion, and gastrointestinal symptoms.

The findings may help determine whether adding electrolytes and taurine to creatine provides additional benefits or produces different physiological responses compared with creatine monohydrate alone.

02

Conditions studied

  • Exercise Performance
  • Cognitive Performance
03

In context

Lead sponsor

University of Northern Iowa is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-40 years.
  • Apparently healthy individuals who are physically active and capable of performing vigorous exercise.
  • Willing and able to complete repeated maximal-intensity cycling tests, bench press exercise, and cognitive assessments.
  • Willing to consume both assigned dietary supplement formulations for 18 days each, separated by a 30-day .
  • Willing to refrain from taking additional creatine or electrolyte supplements during the study, including the washout period.
  • Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular, metabolic, renal, neurological, or musculoskeletal conditions that may contraindicate vigorous exercise or interfere with study outcomes.
  • Current injury or physical limitation that would prevent safe completion of the exercise testing procedures.
  • Current pregnancy or plans to become pregnant during the study.
  • Recent creatine supplementation prior to enrollment.
  • Current use of medications or dietary supplements that may interfere with creatine metabolism, hydration status, exercise performance, cognitive function, or participant safety.
  • Known allergy, intolerance, or to any ingredient in the study supplements.
  • Unwillingness or inability to comply with supplementation, washout, or laboratory testing requirements.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Creatine Monohydrate Followed by Multi-Ingredient Creatine

    Participants will receive creatine monohydrate (5 g/day) with sugar-free flavoring for 18 consecutive days, followed by a 30-day washout period. Participants will then receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period.

    Dietary Supplement: Creatine Monohydrate · Dietary Supplement: Multi-Ingredient Creatine Formulation

  • Experimental
    Multi-Ingredient Creatine Followed by Creatine Monohydrate

    Participants will receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for 18 consecutive days, followed by a 30-day washout period. Participants will then receive creatine monohydrate (5 g/day) with sugar-free flavoring for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period.

    Dietary Supplement: Creatine Monohydrate · Dietary Supplement: Multi-Ingredient Creatine Formulation

Interventions

  • Dietary supplementCreatine Monohydrate

    Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

  • Dietary supplementMulti-Ingredient Creatine Formulation

    Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

06

What researchers measure

Primary outcomes

  1. Total Bench Press Repetitions

    Total number of repetitions completed across three sets of bench press exercise at 70% of baseline one-repetition maximum (1RM), performed to volitional fatigue with one minute of rest between sets.

    Time frame: Baseline and Day 18 of each supplementation period.

  2. Peak Power During Repeated Wingate Tests

    Peak power output (watts) measured during three consecutive 30-second Wingate cycling tests, performed with standardized recovery periods.

    Time frame: Baseline and Day 18 of each supplementation period.

  3. Mean Power During Repeated Wingate Tests

    Mean power output (watts) measured during each of three 30-second maximal-effort Wingate cycling tests.

    Time frame: Baseline and Day 18 of each supplementation period.

  4. Total Work During Repeated Wingate Tests

    Total mechanical work (kilojoules) completed across three 30-second Wingate cycling tests.

    Time frame: Baseline and Day 18 of each supplementation period.

  5. Stroop Interference Reaction Time

    Cognitive performance assessed using a computerized Stroop task completed before exercise and during recovery between repeated Wingate tests. Reaction time (milliseconds) will be used to evaluate changes in cognitive performance as exercise-induced fatigue accumulates.

    Time frame: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

  6. Stroop Task Accuracy

    Percentage of correct responses during a computerized Stroop task administered before exercise and during recovery between repeated Wingate cycling tests.

    Time frame: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Secondary outcomes

  1. Wingate Fatigue Index

    Percentage decline in power output during repeated Wingate tests.

    Time frame: Baseline and Day 18 of each supplementation period.

  2. Rating of Perceived Exertion

    Perceived exertion assessed using the Borg 6-20 scale following each Wingate.

    Time frame: Baseline and Day 18 of each supplementation period.

  3. Blood Lactate Concentration

    Blood lactate concentration (mmol/L) measured following each Wingate.

    Time frame: Baseline and Day 18 of each supplementation period.

  4. Urine Specific Gravity

    Urine specific gravity assessed before and after exercise to evaluate hydration status.

    Time frame: Baseline and Day 18 of each supplementation period.

  5. Blood Sodium Concentration

    Sodium concentration measured using an i-STAT analyzer.

    Time frame: Baseline and Day 18 of each supplementation period.

  6. Blood Potassium Concentration

    Potassium concentration measured using an i-STAT analyzer.

    Time frame: Baseline and Day 18 of each supplementation period.

  7. Gastrointestinal Symptom Severity

    Daily 0-10 ratings of bloating, abdominal discomfort, nausea, diarrhea, constipation, reflux, and overall gastrointestinal discomfort.

    Time frame: Baseline and Day 18 of each supplementation period.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 16, 2026
StartEst.
Nov 13, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940010
Lead sponsor
University of Northern Iowa
Responsible party
Terence Moriarty (Associate Professor, University of Northern Iowa) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 13, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Terence A Moriarty
Contact
terence.moriarty@uni.edu
319-273-6866

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Creatine monohydrate

Start the discussion